Suppr超能文献

关于蛋白激酶你应该了解的十件事:IUPHAR综述14

Ten things you should know about protein kinases: IUPHAR Review 14.

作者信息

Fabbro Doriano, Cowan-Jacob Sandra W, Moebitz Henrik

机构信息

PIQUR Therapeutics, Basel, Switzerland.

Novartis Institutes of Biomedical Research, Basel, Switzerland.

出版信息

Br J Pharmacol. 2015 Jun;172(11):2675-700. doi: 10.1111/bph.13096. Epub 2015 Mar 24.

Abstract

Many human malignancies are associated with aberrant regulation of protein or lipid kinases due to mutations, chromosomal rearrangements and/or gene amplification. Protein and lipid kinases represent an important target class for treating human disorders. This review focus on 'the 10 things you should know about protein kinases and their inhibitors', including a short introduction on the history of protein kinases and their inhibitors and ending with a perspective on kinase drug discovery. Although the '10 things' have been, to a certain extent, chosen arbitrarily, they cover in a comprehensive way the past and present efforts in kinase drug discovery and summarize the status quo of the current kinase inhibitors as well as knowledge about kinase structure and binding modes. Besides describing the potentials of protein kinase inhibitors as drugs, this review also focus on their limitations, particularly on how to circumvent emerging resistance against kinase inhibitors in oncological indications.

摘要

许多人类恶性肿瘤与蛋白质或脂质激酶的异常调节有关,这是由突变、染色体重排和/或基因扩增引起的。蛋白质和脂质激酶是治疗人类疾病的重要靶点类别。本综述聚焦于“关于蛋白激酶及其抑制剂你应该了解的十件事”,包括对蛋白激酶及其抑制剂历史的简短介绍,并以激酶药物发现的展望作为结尾。尽管这“十件事”在一定程度上是任意选择的,但它们全面涵盖了激酶药物发现过去和现在的努力,并总结了当前激酶抑制剂的现状以及关于激酶结构和结合模式的知识。除了描述蛋白激酶抑制剂作为药物的潜力外,本综述还关注它们的局限性,特别是在肿瘤适应症中如何规避对激酶抑制剂新出现的耐药性。

相似文献

3
Therapeutic protein kinase inhibitors.治疗性蛋白激酶抑制剂
Cell Mol Life Sci. 2009 Apr;66(7):1163-77. doi: 10.1007/s00018-008-8539-7.
4
PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.PI3K和mTOR抑制剂:新一代靶向抗癌药物。
Curr Opin Cell Biol. 2009 Apr;21(2):194-8. doi: 10.1016/j.ceb.2008.12.011. Epub 2009 Feb 7.
5
Targeting multiple kinase pathways: a change in paradigm.靶向多种激酶通路:范式的转变。
Clin Cancer Res. 2010 Apr 1;16(7):1973-8. doi: 10.1158/1078-0432.CCR-09-3182. Epub 2010 Mar 9.
7
Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?靶向非催化功能:激酶药物发现的新模式?
J Med Chem. 2022 Feb 10;65(3):1735-1748. doi: 10.1021/acs.jmedchem.1c01978. Epub 2022 Jan 9.
8
Small molecule kinase inhibitors as anti-cancer therapeutics.小分子激酶抑制剂作为抗癌治疗药物。
Mini Rev Med Chem. 2012 May;12(5):399-411. doi: 10.2174/138955712800493915.
9
Kinase Inhibitor Screening in Myeloid Malignancies.髓系恶性肿瘤中的激酶抑制剂筛选
Hematol Oncol Clin North Am. 2017 Aug;31(4):693-704. doi: 10.1016/j.hoc.2017.04.004. Epub 2017 May 19.

引用本文的文献

7
Kinase-Targeted Therapies for Glioblastoma.胶质母细胞瘤的激酶靶向治疗
Int J Mol Sci. 2025 Apr 15;26(8):3737. doi: 10.3390/ijms26083737.

本文引用的文献

2
The landscape of kinase fusions in cancer.癌症中激酶融合的情况
Nat Commun. 2014 Sep 10;5:4846. doi: 10.1038/ncomms5846.
5
Allosteric IGF-1R Inhibitors.变构胰岛素样生长因子-1受体抑制剂
ACS Med Chem Lett. 2010 May 18;1(5):199-203. doi: 10.1021/ml100044h. eCollection 2010 Aug 12.
6
Ibrutinib resistance in chronic lymphocytic leukemia.慢性淋巴细胞白血病中的依鲁替尼耐药性。
N Engl J Med. 2014 Jun 12;370(24):2352-4. doi: 10.1056/NEJMc1402716. Epub 2014 May 28.
7
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.尼达尼布治疗特发性肺纤维化的疗效和安全性。
N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验